This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Vildagliptin

From Proteopedia

Revision as of 10:17, 13 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Vildagliptin, better known as Galvus, ([[___]])

Drag the structure with the mouse to rotate

Better Known as: Galvus

  • Marketed By:
  • Major Indication:
  • Drug Class:
  • Date of FDA Approval (Patent Expiration):
  • 2009 Sales:
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

DPP4 Inhibitor Pharmacokinetics
Parameter Vildagliptin
(Galvus) 		Sitagliptin
(Januvia) 		Saxagliptin
(Onglyza)
Tmax (hr) 1.75 1-4 2
Cmax (ng/ml) 290 330 34
Bioavailability (%) 85 87 67
Protein Binding (%) 9 38 0
T1/2 (hr) 2-3 12.4 2.5
AUC (ng/ml/hr) 1610 3470 101
IC50 (nM) 3 18 50
Renal Clearance (L/h) 13.0 21.0 13.8
Volume Distribution (L) 71 198 151
Dosage (mg) 100 100 5
Metabolism Hydrolysis Hepatic (CYP3A4 & CYP2C8) Hepatic (CYP3A4)

For Pharmacokinetic Data References, see: References

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner

Retrieved from "http://52.214.119.220/wiki/index.php/Vildagliptin"
Personal tools